Both in Biotechnology
LENZ Therapeutics vs Humacyte
Over the past year LENZ returned −87.3% and HUMA returned −73.2%; their daily moves had a correlation of 0.28.
LENZ −87.3% HUMA −73.2%Growth of $1, one year, split-adjusted
| Metric | LENZ | HUMA |
|---|---|---|
| Price | $3.55 | $0.4260 |
| Market cap | $111.5M | $118.3M |
| Today | +16.39% | +7.01% |
| 1 month | −1.1% | −14.8% |
| 6 months | −60.9% | −52.8% |
| Year to date | −77.8% | −55.6% |
| 1 year | −88.1% | −74.5% |
| Revenue growth (YoY) | +9.7% | +34.9% |
| Gross margin | 94.9% | −203.2% |
| Net margin | −581.8% | −9064.5% |
| P/E (TTM) | — | — |
| Price / sales | 5.2× | 55.8× |
| Net cash | $220.0M | $13.7M |
| Dividend yield | — | — |
| Volatility (60d) | 77.2% | 106.8% |
| Short % of float | 46.7% | 11.9% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).